Nanmo Biotechnology
Nanmo Biotechnology is a Shanghai-listed life sciences firm that designs and supplies gene-modified animal models (mice, rats, cell lines) and integrated preclinical CRO services to pharmaceutical companies, biotech firms, and academic research institutions across China, the US, and the UK.
- Company typePublic
- Founded2000
- HeadquartersShanghai, China
- Headcount101–250
- GTM typeB2B
- OfferingServices
What Nanmo Biotechnology does
Commercially, Nanmo serves three customer segments: pharmaceutical and biotech companies (including Akeso, Kelun-Biotech, Baili-Tianqing, Summit Therapeutics, BMS, and Merck/MSD), academic and government research institutions (including the Chinese Academy of Sciences), and contract research organizations. Revenue is generated through one-time model license sales (catalog and custom), professional services fees for preclinical CRO studies, and recurring supporting services for breeding, cryopreservation, animal room management, and genotyping. Pricing is quote-based rather than publicly disclosed, and go-to-market is sales-led via direct enterprise accounts, technical hotlines, WeChat consultation, and content marketing through the company website and industry conferences such as ASCO. The company is listed on the Shanghai Stock Exchange STAR Market and serves customers across China, the United States, and the United Kingdom.
Nanmo Biotechnology firmographics
Firmographics- Name
- Nanmo Biotechnology
- Legal name
- 上海南方模式生物科技股份有限公司
- Website
- https://modelorg.com
- Company type
- Public
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Nanmo Biotechnology is a Shanghai-listed life sciences firm that designs and supplies gene-modified animal models (mice, rats, cell lines) and integrated preclinical CRO services to pharmaceutical companies, biotech firms, and academic research institutions across China, the US, and the UK.
- Ownership category
- akta.pro rank
Nanmo Biotechnology industry classification
Industry- Product category
- Preclinical Research Models and CRO Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)
- akta.pro secondary industry
- In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)
Keywords
Where Nanmo Biotechnology is headquartered
LocationHeadquarters
- HQ city
- Shanghai
- HQ country
- China
- HQ region
- Asia
Offices1 record
Markets served
Nanmo Biotechnology business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Ready-made Model Sales: Sale of catalog genetic modification models including knockout mice, humanized mice, immunodeficient mice, tool mice, and disease models. Over 16,000 ready-made models available.
- Custom Model Development: Bespoke gene modification model services using SmartEddi® system for gene knockout, knock-in, point mutations, and humanization based on client specifications.
- Preclinical CRO Services: Contract research services including in vivo/in vitro efficacy testing, toxicology, and pathology services for drug discovery.
- Supporting Services: Breeding services, cryopreservation, animal room management, and genotyping services.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Nanmo Biotechnology product offering
Product offeringCore offering
Nanmo Biotechnology develops, breeds, and sells genetically modified laboratory animal models (mice, rats, zebrafish) and cell lines for life science research and preclinical drug discovery. Its portfolio includes 16,000+ catalog ready-made models, custom gene-modified model generation services delivered through its SmartEddi® platform, and integrated preclinical CRO services spanning tumor, metabolic, inflammation/autoimmune, and neurological disease efficacy evaluation. Customers include pharmaceutical and biotech companies, academic research institutions, and CROs in China and internationally.
Product overview
Nanmo Biotechnology (南模生物) is a Shanghai-based biotech company (stock code: 688265) specializing in gene-modified model organisms, offering an integrated portfolio of products and preclinical CRO services. The core offering comprises over 16,000 finished gene-modified animal models (mice, rats, cell lines) and custom model generation services through the SmartEddi intelligent customization system. The preclinical CRO services span tumor efficacy evaluation (syngeneic, CDX, PDX, humanized models), metabolism/cardiovascular disease evaluation, inflammation/autoimmune disease evaluation, neurological disease evaluation, cell line services, in vitro/vivo efficacy testing, and toxicology/pathology services. Supporting services include model breeding, preservation, animal management, and genotyping.
Differentiator
Problem solved
Functional benefit
Brands
- SmartEddi: SmartEddi intelligent mouse model customization system - an intelligent customization system for quickly obtaining mouse model customization solutions
- U-DMbase
Quantifiable outcome
- Supporting research published in top-tier journals including Cell, Nature, Science, and their sub-journals
- +1 more outcomes
Companies that use Nanmo Biotechnology
Customer profileNamed customers7 records
Segments3 records
Ideal customer profiles3 records
Nanmo Biotechnology technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Nanmo Biotechnology partnerships and signals
Strategic signalScale indicators5 records
Recent moves6 records
Expansion highlights5 records
Nanmo Biotechnology competitors and assessment
Company assessmentBroad incumbents
- Jackson Laboratory: Global leader in mouse model distribution and genetically defined mouse strains with deep academic and pharma penetration. Competes with Nanmo on catalog model distribution and serves as the international benchmark for quality and IP-rich model libraries.
- WuXi AppTec: China-based global CRO/CDMO with preclinical biology services including animal model studies. Overlaps with Nanmo in preclinical efficacy testing, though much broader in service scope and scale.
- Charles River Laboratories: Global CRO offering preclinical research services including model organism supply and efficacy/safety evaluation. Overlaps with Nanmo's preclinical CRO segment, particularly for multinational pharma clients, though Charles River is far broader in scope.
Regional players
- Inotiv: US-based preclinical CRO with model organism supply and contract research services. Comparable business model combining model supply with preclinical studies, though primarily serving North American customers.
- Pharmaron: China-rooted global CRO offering preclinical services including animal model-based drug efficacy/toxicology evaluation. Comparable in CRO services scope with both Chinese and international footprint.
Direct peers
- Biocytogen: China-based biotech offering humanized mouse models (RenMab/RenLite platforms) and preclinical services. Direct competitor with proprietary humanized antibody platforms and similar pharma/biotech customer profile.
- GemPharmatech: Chinese model organism CRO specializing in gene-modified mouse models and preclinical services. Direct competitor offering similar knockout, knockin, and humanized mouse capabilities, with overlapping customer base in Chinese biotech.
- Cyagen Biosciences: China-based and US-operating provider of custom genetically modified mouse/rat models and cell line services. Direct competitor in custom model generation with similar CRISPR/Cre-Lox technology stack.
- Crown Bioscience (JSR Life Sciences): Preclinical CRO with extensive humanized mouse and oncology model portfolio. Directly comparable in the preclinical efficacy evaluation segment, particularly for oncology and immuno-oncology applications.
- Taconic Biosciences: Specialty provider of genetically engineered mice and rats with strong pharma/biotech customer base. Directly comparable business model focused on catalog and custom model sales, serving similar drug discovery end markets.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Nanmo Biotechnology financial estimates
Financial estimateRevenue estimate
Valuation estimate
Nanmo Biotechnology leadership team
Management profileNumber of profiles
Profiles1 record
Nanmo Biotechnology funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Nanmo Biotechnology M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Nanmo Biotechnology
What does Nanmo Biotechnology do?
Nanmo Biotechnology develops, breeds, and sells genetically modified laboratory animal models (mice, rats, zebrafish) and cell lines for life science research and preclinical drug discovery. Its portfolio includes 16,000+ catalog ready-made models, custom gene-modified model generation services delivered through its SmartEddi® platform, and integrated preclinical CRO services spanning tumor, metabolic, inflammation/autoimmune, and neurological disease efficacy evaluation. Customers include pharmaceutical and biotech companies, academic research institutions, and CROs in China and internationally.
Is Nanmo Biotechnology a public or private company?
Nanmo Biotechnology is a public company. It is classified as public and is currently operating.
When was Nanmo Biotechnology founded?
Nanmo Biotechnology was founded in 2000. It employs 101 to 250 people.
Where is Nanmo Biotechnology based?
Nanmo Biotechnology is headquartered in Shanghai, China, in the Asia region.
How does Nanmo Biotechnology make money?
Four revenue lines are on record. Ready-made Model Sales are the primary driver. The others are custom Model Development, preclinical CRO Services and supporting Services.
Who are Nanmo Biotechnology's main competitors?
Broad incumbents on record are Jackson Laboratory, WuXi AppTec and Charles River Laboratories. Regional players are Inotiv and Pharmaron. Direct peers are Biocytogen, GemPharmatech, Cyagen Biosciences, Crown Bioscience (JSR Life Sciences) and Taconic Biosciences.
Does Nanmo Biotechnology have an API?
No public API is recorded for Nanmo Biotechnology.
What industry is Nanmo Biotechnology in?
Nanmo Biotechnology's product category is Preclinical Research Models and CRO Services. Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems). Its NAICS code is 541714 and its SIC code is 8731.